The IL17RB Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the HGC-27 human gastric carcinoma cell line, with targeted disruption of the IL17RB gene. This loss?of?function model abolishes expression of the IL?25 receptor (IL?17RB), enabling detailed study of IL?25 signaling in a gastric cancer context. The polyclonal format retains genetic heterogeneity, supporting pooled functional assays and high?throughput screening.
HGC-27 is an undifferentiated gastric carcinoma cell line established from a lymph node metastasis of a gastric adenocarcinoma patient. It is widely used as a model for metastatic gastric cancer, exhibiting rapid growth and genomic alterations typical of advanced disease. Employing HGC-27 as the host for IL17RB knockout provides a physiologically relevant platform to dissect IL?25-related pathways in aggressive gastric carcinoma.
IL17RB encodes the receptor for IL?25 (IL?17E). Upon ligand binding, IL?17RB heterodimerizes with IL?17RA, recruiting the adaptor Act1 (TRAF3IP2) and TRAF6 to activate NF???B and MAPK (ERK, JNK, p38) cascades. Downstream targets include pro?inflammatory mediators like IL?6, IL?8, CXCL1, and CCL20. Additionally, IL?25/IL?17RB signaling engages the JAK/STAT pathway, leading to STAT6 phosphorylation and GATA3 induction, driving type 2 immune responses. Expression of IL17RB is regulated by IL?4, IL?13, and TSLP, placing the receptor at a key node in allergic inflammation and epithelial homeostasis.
In gastric cancer, IL?25/IL?17RB signaling may contribute to tumor microenvironment inflammation, promoting tumor cell proliferation and survival. Knockout of IL17RB in HGC-27 cells permits dissection of these tumor-intrinsic roles, enabling assessment of NF???B? and MAPK?driven protumorigenic programs and potential crosstalk with JAK/STAT pathways. The model is valuable for studying how type 2 cytokine networks influence gastric carcinoma progression and metastasis.
Research applications include IL?25 stimulation assays followed by phospho?NF???B or phospho?MAPK immunoblotting, RT?qPCR analysis of downstream targets (IL6, CXCL1, CCL20), and multiplex cytokine secretion profiling. The cells are also suited for proliferation, migration, and invasion studies, as well as immune cell co?culture models to explore paracrine signaling. For drug target validation, they can be used in inhibitor screens or rescue experiments. For inquiries, please contact Ascent Research.
